AXL and prostate carcinoma: Interestingly, AXL is upregulated and activated in docetaxel-resistant prostate cancer cell lines, and AXL blockade in these cells, either by siRNA targeting or treatment with the non-specific tyrosine kinase inhibitor amuvatinib (MP470), induced apoptosis and reduced cell migration and invasion [309].